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Background: Cholera is a highly infectious diarrheal disease spread via fecal contamination of water and food sources;
it is endemic in parts of Africa and Asia and recent outbreaks have been reported in Haiti, the Zambia and
Democratic Republic of the Congo. If left untreated, the disease can be fatal in less than 24 h and result in
case fatality ratios of 30–50%.
Cholera disproportionately affects those living in areas with poor access to water and sanitation: the long-term public
health response is focused on improving water and hygiene facilities and access. Short-term measures for infection
prevention and control, and disease characterization and surveillance, are impaired by diagnostic delays: culture
methods are slow and rely on the availability of infrastructure and specialist equipment. Rapid diagnostic tests
have shown promise under field conditions and further innovations in this area have been proposed.
Methods: This paper is the protocol for a systematic review focused on identifying current technologies and
methods used for cholera diagnosis in stool, and detection in water. We will synthesize and appraise information on
product technical specifications, accuracy and design features in order to inform infection prevention and control and
innovation development.
Embase, MEDLINE, CINAHL, Proquest, IndMed and the WHO and Campbell libraries will be searched. We will include
studies reporting on field evaluations, including within-study comparisons against a reference standard, and laboratory
evaluations reporting on product validation against field stool or water samples. We will extract data according
to protocol and attempt meta-analyses if appropriate given data availability and quality.
Discussion: The systematic review builds on a previous scoping review in this field and expands upon this by
synthesising data on both product technical characteristics and design features. The review will be of particular
value to stakeholders engaged in diagnostic procurement and manufacturers interested in developing cholera
or diarrheal disease diagnostics.
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Table 1 Review questions
The systematic review we propose addresses the following research
questions:
1. What cholera diagnosis and detection products are currently
available?
2. How do the above-identified products perform with respect to their
specificity, sensitivity and accuracy?
3. What challenges arise in the deployment and use of current
diagnostic products and detection methods?
4. What design characteristics should products have to enable improved
cholera IPC and surveillance?
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One hundred sixty years have passed since John Snow
identified the Broad Street water pump as the source of
the 1864 London cholera outbreak [1]. Today, cholera is
largely absent across high-income countries. However,
the disease persists in low-resource and humanitarian
settings where it disproportionately affects those living
in overcrowded areas with poor or no access to clean
water and sanitation [2–4]. In 2015 alone, the World
Health Organization (WHO) recorded 172,454 cholera
cases and 1304 deaths; 41% of these were reported in
Africa, with a further 37 and 21% respectively originat-
ing in Asia and the Americas [3]. The aforementioned
estimates are a likely underestimation of the true toll of
the disease: modelling exercises predict 1.4 to 4.0 million
cholera cases occur worldwide annually, resulting in ap-
proximately 21–143,000 deaths [5]. Cholera is endemic
in many parts of Africa [6], and recent outbreaks have
been reported in the Democratic Republic of the Congo,
Zambia, the Dominican Republic and Haiti as well as
Central and West Africa [2, 3, 7].
Cholera is a highly infectious diarrheal disease caused
by the Vibrio cholerae O1 and 139 bacteria [8]. Adults
and children are equally susceptible and become ill upon
ingesting contaminated foods or water [6, 9]. Symptoms
of affected patients include severe dehydration, vomiting
and characteristic “rice water stool”; if left untreated, the
disease can be fatal in less than 24 h leading to high
population level case fatality rates (30–50%) [9]. While
treatment is inexpensive and easy to administer—it con-
sists of the administration of oral rehydration solution
and rest, cholera infection prevention and control (IPC)
and surveillance are not [6, 8–11]. Two issues are of par-
ticular relevance in this regard.
First, 80% of cholera-affected patients do not exhibit
typical symptoms; infected persons may therefore un-
knowingly propagate the spread of the disease [3, 9].
Cholera bacteria can live up to 4 weeks in an infected
persons’ stool, spreading to food sources or contaminat-
ing the water supply of communities [9].
Second, diagnosis is costly and disease and outbreak
confirmation rely on the presence of laboratory infra-
structure [8, 9, 12]. Culture methods are the current
diagnostic gold standard [13], but prove to be time-
consuming (more than 24 h) and assume the presence
of suitable laboratory equipment, reagents and human
resources skilled in performing appropriate tests [8]. As
laboratories and skilled technicians are in short supply
in humanitarian and low-resource settings, rapid diag-
nostic tests (RDTs) ready for immediate field deploy-
ment have been developed [10, 12]. RDTs appear
increasingly fast and easy to use, but are prohibitively
expensive and insufficiently sensitive and specific to aid
in cholera detection (versus diarrhoeal diseases) [8, 13].Timely cholera IPC and improved surveillance are
predicated on the availability, and procurement, of inex-
pensive and accurate diagnostic products [6, 10, 11, 14].
To inform product development efforts, as well as offer
evidence to stakeholders engaged in cholera diagnostic
product procurement, up-to-date information on the
comparative accuracy, technical specification and design
of currently available technologies is needed.
Methods and systematic review design
Study design and scope
This paper serves as a protocol for a systematic review
that aims to identify any relevant cholera diagnosis and
detection products for use in either stool or water glo-
bally and appraise the ancillary evidence base.
Review objectives
In line with study questions (Table 1), the review seeks
to:
1) Document technical specifications of cholera
diagnosis/detection products and appraise the
ancillary evidence base, by:
a. Identifying products currently used (or about to
be commercially available) for cholera diagnosis
in stool and detection in water;
b. Synthesising information on product technical
characteristics (e.g. detection target and limit,
accuracy, reliability);
c. Reviewing the sensitivity and specificity of available
testing products, if appropriate given data quality,
synthesising quantitative information on test
performance in a meta-analysis;
d. Critically appraising the quality of studies forming
the evidence base for each diagnostic product.
2) To provide a structured narrative account of issues
arising in product deployment and use, by:
a. Extracting quotes from included studies on product
pricing, availability, design features (e.g. ease of use)
and accounts of product use;
b. Coding, thematically grouping and iteratively
interpreting the data to identify how/why certain
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successfully deployed for cholera IPC or surveillance.Scoping searches
Scoping searches on the review topic were conducted in
August 2016 and indicate a dearth of review materials
available relating to cholera diagnosis. Searches included
PROSPERO, the Cochrane Library and MEDLINE; the
former databases were searched using the term “chol-
era”; in MEDLINE, the terms “diagnosis” or “detection”
were added.
PROSPERO indicated five systematic reviews on chol-
era are on-going [15–19]; topics ranged from the safety
and effectiveness of antibacterial treatment [15] to the
effectiveness of oral cholera vaccine when used reactively
[18]. The Cochrane Library held records of eight
Cochrane [20–27] and four Centre for Reviews and Dis-
semination (CRD) reviews of similar focus to PROS-
PERO protocols [28–31]; documents explored the
effects and impact of vaccines and chemoprophylaxis
[26, 27, 29, 31], antimicrobial and antibiotic treatment
[25, 31] and oral rehydration salts [23, 28].
A review of titles in MEDLINE identified a journal
article of particular relevance by Dick et al. [12]. In this re-
view, the authors search the English language biblio-
graphic and grey literature since 1990 and identify and
describe the technical specifications of 24 commercially
available diagnostic products available for use in low-
resource and humanitarian settings [12]. The authors rank
diagnostic products that have been evaluated in field
accuracy studies according to positive and negative pre-
dicted values; five rapid diagnostics are identified as show-
ing particular promise for further use in IPC/surveillance
(COAT, Institute Pasteur Cholera Dipstick, SMART, Insti-
tute Pasteur Dipstick and Medicos). Dick et al. recom-
mend the latter products for further evaluation via
independent field studies [12].
While the review by Dick et al. offers a comprehensive
starting point for research on cholera diagnostics, the re-
view was not systematic and is likely to have overlooked
studies of relevance reported outwith English. Addition-
ally, minimal details on the processes of review manage-
ment, study selection and data extraction are noted: it is
unclear who conducted searches, selected studies and
how data were extracted, aggregated and primary studies
appraised. Notably, the scoping review synthesises data
on product technical specifications (i.e. sensitivity/speci-
ficity, turn-around time), but neglects to present infor-
mation on product design (e.g. ease of use, training
requirements) or pricing (e.g. price per test and cost per
test-use). Information on the latter issues is highly per-
tinent given the variability in available human resources
to carry out cholera IPC/surveillance, high unit price ofrapid diagnostic tests and limited infrastructure to sup-
port laboratory-based diagnosis confirmation [8, 9, 12].
Search strategy and information sources
We will search MEDLINE, CINAHL, Embase, IndMed,
Scopus, Proquest, the Campbell collaboration and the
WHO libraries (WHOLIS) (see Fig. 1). Tables 2 and 3 il-
lustrate search strings to be used for MEDLINE and
CINAHL; similar searches will be conducted in the
remaining databases listed and studies selected as per cri-
teria outlined below. The Cochrane Library has been ex-
cluded from searches as no trials or articles of relevance
on cholera diagnostic products or methods were identified
during scoping searches. In addition to the above sources,
we will search reference lists from relevant articles and in-
clude the studies identified by Dick et al. [12] We will also
search grey literature (e.g. OpenGrey).
Study and data management
KD will act as main reviewer and data custodian. The
study will be conducted in line with the CRD’s guidance
on diagnostic accuracy systematic reviews [32].
Two reviewers (JF, KD) will screen all titles and ab-
stracts for inclusion. Articles identified will be down-
loaded directly into EndNote/Zotero for screening. Data
extraction will be conducted by two reviewers, in dupli-
cate and blinded as per standard systematic review
methodology. Information on pre-specified items will be
extracted into a Microsoft Excel document (see the
“Data extraction” section below and Additional file 1).
Following resolution of disagreements, a collated version
of extracted data will be made available to the review
team for analysis.
Disagreements between reviewers will be resolved by
consultation of a third reviewer (FO).
Study selection
Figure 2 outlines the study selection and data extraction
procedures employed. We will include studies from any
global settings reporting on any diagnostic technologies
targeting cholera O1 or O139, of both classical and El
Tor biotypes and Ogawa and Inaba serotypes [33].
We will include primary diagnostic accuracy studies
(laboratory or field based) that focus on the evaluation
of methods or products used in cholera diagnosis in hu-
man stool or detection in water. Prospective studies and
studies retrospectively evaluating diagnostic or detection
products will be included. We acknowledge that culture
methods are considered the gold standard for cholera
diagnosis and detection; however, we will include any
studies reporting on the performance of index tests
against a specified comparator test. To be included,
studies must report the sensitivity and specificity of eval-
uated diagnostic products/methods.
Fig. 1 Systematic review process. This figure provides details on the search, abstract review, data extraction and synthesis and analysis processes
of the review
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outwith English be retrieved, the author group will com-
mit to consulting translators to extract relevant data.
Only articles beyond 1990 will be reviewed; this reflects
the time of significant medical device and product devel-
opment advances in the field of cholera diagnosis as re-
ported by Dick et al. [12].Data extraction
Full texts of included abstracts will be retrieved and data
extracted as per the pre-specified template (Additional file 1).
The template has been tailored to the current study and
closely mirrors the Cochrane group’s data extraction tem-
plate for systematic reviews [34].Table 2 Search terms used to search MEDLINE
S1 (MH “Cholera”) OR “cholera” OR (MH “Cholera Toxin”)
S2 (MH “Diagnosis”) OR “diagnosis” OR (MH “Early Diagnosis”) OR (MH
“Diagnosis, Differential”)
S3 (MH “Limit of Detection”) OR “detection”
S4 (MH “Diarrhea+”) OR “diarrhoea”
S5 (MH “Water”) OR “water” OR (MH “Drinking Water”) OR (MH “Water
Pollution”) OR (MH “Water Wells”) OR (MH “Water Supply”) OR (MH “Water
Quality”) OR (MH “Waste Water”)
S6 AB choler*
S7 AB diagnos* OR AB detect*
S8 AB stool OR AB diarrh* OR AB water
S9 S2 OR S3
S10 S4 OR S5
S11 S1 AND S9 AND S10
S12 S6 AND S7 AND S8
S13 S11 OR S12
S14 Limit S13 to (yr = “1990-current”)We will extract data on the following domains and
items among others:
 Study characteristics: study design, duration and aims,
populations included and sample characteristics,
products evaluated, outcomes noted and statistical
methods used;
 Diagnostic product or method characteristics: index
and/or reference product name, technical specifications
(e.g. test format, turn-around time, disease target and
stability of test under transport and storage conditions),
cost (e.g. price per test and cost per use of test),
product design and use (e.g. handling, user training,
availability in deployment settings).Table 3 Search string used to search CINAHL
S1 AB choler*
S2 AB diagnos* OR AB detect*
S3 AB stool OR AB fec* OR AB faec* OR AB diarrh* OR AB water
S4 S1 AND S2 AND S3
S5 (MH “Cholera”) OR “cholera”
S6 (MH “Diagnosis”) OR “diagnosis” OR (MH “Diagnosis, Laboratory”) OR
(MH “Early Diagnosis”)
S7 (MH “Diarrhea”) OR “diarrhoea”
S8 (MH “Feces”) OR “feces”
S9 stool
S10 (MH “Water”) OR (MH “Water Pollution”) OR (MH “Water Supply”) OR
(MH “Water Microbiology”)
S11 S2 OR S6
S12 S7 OR S8 OR S9 OR S10
S13 S5 AND S11 AND S12
S14 S4 OR S13
S14 Limit S13 to Jan 1990-Sept 2017
Fig. 2 Selection criteria applied to abstracts retrieved via literature searches. This figure is a decision tree outlining how study selection criteria
will be applied during abstract screening
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mentioned: the data extraction sheet has been
tailored to the specific type of accuracy study
conducted, either laboratory or field based.
For both reference and index tests, data will
be extracted on diagnostic method description,
test content and ancillary diagnostic procedures
undertaken, economic or resource requirements
of testing, test accuracy metrics (e.g. sensitivity,
specificity, negative and positive predictive
values).Data synthesis
We will use three methods for synthesis of extracted
data (see Fig. 1):
 Narrative and quantitative synthesis
All studies, irrespective of quality, will be included in a
narrative synthesis. As per Popay et al. [32, 35], we will
synthesise insights from the reviewed literature in order
to provide a theory of how cholera diagnostic products
are used, including an account of deployment challenges
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appraise the studies and products noted therein accord-
ing to study type, setting and population characteristics,
and type of diagnostic/detection product or method.
Should meta-analyses not be appropriate (see the
below section), we will synthesise quantitative data
and provide a descriptive account of diagnostic
method and accuracy metrics.
 Meta-analyses
All texts will undergo screening for inclusion in meta-
analysis. We anticipate conducting meta-analyses only
for field evaluation studies that use culture methods as
the reference standard for cholera detection (see
Additional file 2). We will use sensitivity analyses to
explore the effect of study quality on meta-estimates.
Meta-analyses will be organized in sub-groups depend-
ing on the diagnostic product or method type evaluated,
e.g. dipstick tests targeting lipopolysaccharides vs.
culture methods. Meta-estimates of test sensitivity and
specificity will be calculated; we will additionally calcu-
late I2 statistics. Should a substantial number of studies
report diagnostic accuracy in comparison to reference
standards other than culture, a further meta-analysis
may be conducted.
We will follow the guidance of the Cochrane group
when conducting meta-analyses [36].
 Qualitative meta-summary
For extraction items focused on capturing product de-
sign characteristics, reviewers will extract quotes from
appraised documents. The specific data items will serve
as the basis of a deductive coding framework. Reviewers
will extract any additional quotes of relevance in a fur-
ther “other” named extraction column; the latter will
then undergo inductive coding. All quotes will form part
of a thematic analysis and qualitative meta-summary as
per Sandelowski et al. [37].Assessment of risk of bias and quality of evidence
We will assess the risk of bias in individual studies via
use of the QUADAS2 tool [38]—tailored specifically to
study purposes and included as a separate worksheet in
the data extraction template (Additional file 1). In
addition to this, we will assess confidence in cumulative
evidence by following a GRADE approach [39].Reporting
We will follow PRISMA reporting guidelines [40] and
enclose a PRISMA-P checklist as an Additional file 2.Discussion
We propose to undertake a systematic review of stud-
ies evaluating the accuracy, design and availability/pri-
cing of products for cholera diagnosis in stool or
detection in water. The review is particularly timely
given recent international efforts in cholera surveil-
lance and the specified need for improved diagnostic
capacity [41]. The systematic review will assist both
health care professionals engaged in selecting diagnos-
tic devices for procurement and manufacturers and
researchers engaged in cholera-specific diagnostic
product development.
We acknowledge several limitations. First, search
terms are broad and may retrieve a particularly large
number of studies; materials retrieved are likely to be
highly heterogeneous, spanning both laboratory and
field evaluations of cholera diagnostic and detection
products. In line with Dick et al. [12], we note that
this is necessary in order for the review to capture
up-to-date information on all diagnostic products
available for supporting cholera IPC/surveillance. To
standardize data extraction and ensure we systematic-
ally appraise evidence, we have tailored data extrac-
tion to study type (either field or laboratory) and will
report on all extracted data in detail in line with the
GRADE approach [39].
Second, we are restricting inclusion to laboratory stud-
ies validating index tests against field samples and to
field evaluations reporting within-study comparisons
against a reference test. This exclusion policy is designed
to capture information only on products most likely to
proceed to use in the field in the near future. This im-
plies that proof-of-concept or incipient evaluation stud-
ies reporting on innovative product development will be
excluded. To still capture information on products in
early stages of development, we will produce detailed
tables noting studies excluded from our analysis.
Third, we acknowledge that meta-analyses may not be
possible due to a restricted and low-quality evidence
base in this area. In particular, scoping searches suggest
studies may omit reporting population characteristics,
confounders and diagnostic thresholds. Dick et al. add-
itionally note that diagnostic evaluations are frequently
conducted by product developers themselves, potentially
biasing reporting and study design [12]. We will rigor-
ously assess the risk of bias within studies and across the
body of evidence in order to assess the appropriateness
of conducting a meta-analysis.
Despite the above limitations, we emphasize the sys-
tematic review proposed here is of particular research
and practical value. The study aims to offer a compre-
hensive, up-to-date account of products currently (or
soon to be) available for cholera diagnosis in low-
resource settings. In contrast to previous work, we seek
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uct technical characteristics but also design features and
notes on product availability/pricing. This will be of par-
ticular use to stakeholders directly engaged in cholera
IPC and surveillance when selecting diagnostic products
for investment and use in cholera outbreaks
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